Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation

Bone Marrow Transplantation
S DermimeA John Barrett

Abstract

We studied patients relapsing with myeloid leukemias following allogeneic bone marrow transplantation (BMT) for evidence of immune escape by clonal evolution of the leukemia. Relapsed cells from four out of five patients had a reduced ability to stimulate proliferation of lymphocytes from an HLA-mismatched responder. There was decreased susceptibility to lysis by CTL in three and reduced susceptibility to NK-mediated lysis in one. Relapsed leukemias had marked alterations in expression of critical surface molecules involved in immune responsiveness. Three had decreased expression of MHC class I and II, with no change or increase in CD54 (ICAM-1) or CD80 (B7.1). None of these responded to treatment with donor lymphocytes. Three patients showed no change, or increased expression of MHC with no change or decrease in ICAM-1 or B7.1. Two achieved remission - one in response to donor lymphocytes and one following withdrawal of cyclosporine. In one patient transplanted with myelodysplastic syndrome in transformation, interferon-gamma upregulated expression of MHC molecules in relapsed cells and increased their stimulatory capacity and target susceptibility to unmatched responder lymphocytes. These results suggest that immune escape th...Continue Reading

Citations

Jan 1, 1997·Stem Cells·A J Barrett
Dec 5, 2002·International Journal of Hematology·Hee-Je KimChun-Choo Kim
May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
Aug 28, 2009·Cancer Immunology, Immunotherapy : CII·Nicola HardwickFarzin Farzaneh
Mar 5, 2013·Current Hematologic Malignancy Reports·Raya MawadJohn M Pagel
Aug 19, 2003·Leukemia Research·Gregor S D ReidKirk R Schultz
Jul 11, 2000·British Journal of Haematology·L C NorburyS E Christmas
Jul 31, 2009·The New England Journal of Medicine·John Barrett, Bruce R Blazar
May 1, 2009·Immunotherapy·Lisbeth Barkholt, Marco Bregni
Sep 17, 2015·International Journal of Cancer. Journal International Du Cancer·Eva DistlerUdo F Hartwig
Nov 8, 2001·Leukemia & Lymphoma·R E Clark, S E Christmas
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Dec 5, 2012·Seminars in Oncology·Dolores Grosso, Neal Flomenberg
Dec 16, 2010·Cancer Genetics and Cytogenetics·Machiko KawamuraYasuhide Hayashi
Oct 26, 2010·Transplantation Proceedings·R Casalegno-GarduñoM Schmitt
Jun 1, 1997·Baillière's Clinical Haematology·A J Barrett, F van Rhee
Feb 29, 2008·American Journal of Hematology·Osamu ImatakiToshihiko Ishida
Jun 10, 2010·Clinical and Experimental Immunology·A J Barrett, K Le Blanc
Oct 9, 2009·Leukemia Research·Anish ThomasChirag M Shah
Mar 18, 2006·Experimental Hematology·Roman IvanovSaskia Ebeling
Jul 14, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Esra Terzi DemirsoyMehmet Cengiz Erçin
May 9, 2000·Memórias do Instituto Oswaldo Cruz·J C Voltarelli
Nov 1, 2018·The New England Journal of Medicine·Matthew J ChristopherJohn F DiPersio
Dec 12, 2002·Oncogene·Jeffrey J MolldremSijie Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.